Pictet Asset Management Sa Fate Therapeutics Inc Transaction History

Pictet Asset Management Sa

  • $83.4 Billion
  • Q2 2023

A detailed history of Pictet Asset Management Sa transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Pictet Asset Management Sa holds 1,090,260 shares of FATE stock, worth $2.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,090,260
Previous 1,199,241 9.09%
Holding current value
$2.5 Million
Previous $6.84 Million 24.08%
% of portfolio
0.01%
Previous 0.01%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023
SELL
$4.76 - $6.59 $518,749 - $718,184
-108,981 Reduced 9.09%
1,090,260 $5.19 Million
Q1 2023

May 10, 2023
SELL
$4.24 - $11.12 $13,203 - $34,627
-3,114 Reduced 0.26%
1,199,241 $6.84 Million
Q4 2022

Feb 13, 2023
SELL
$9.86 - $23.83 $9.35 Million - $22.6 Million
-947,921 Reduced 44.08%
1,202,355 $12.1 Million
Q3 2022

Nov 14, 2022
BUY
$21.04 - $36.06 $1.01 Million - $1.74 Million
48,115 Added 2.29%
2,150,276 $48.2 Million
Q2 2022

Aug 09, 2022
BUY
$17.78 - $42.39 $13.2 Million - $31.5 Million
743,525 Added 54.73%
2,102,161 $52.1 Million
Q1 2022

May 13, 2022
SELL
$29.67 - $60.28 $1.56 Million - $3.18 Million
-52,705 Reduced 3.73%
1,358,636 $52.7 Million
Q4 2021

Feb 10, 2022
BUY
$47.84 - $64.34 $21.8 Million - $29.4 Million
456,204 Added 47.76%
1,411,341 $82.6 Million
Q3 2021

Nov 12, 2021
BUY
$59.27 - $95.73 $56.6 Million - $91.4 Million
955,137 New
955,137 $56.6 Million

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Pictet Asset Management Sa Portfolio

Follow Pictet Asset Management Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pictet Asset Management Sa, based on Form 13F filings with the SEC.

News

Stay updated on Pictet Asset Management Sa with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email